More from Renaissance Capital

UK-based cannabinoid therapeutics developer GW Pharmaceuticals files for US IPO

By Renaissance Capital,  March 19, 2013, 03:42:23 PM EDT

GW Pharmaceuticals, which develops and commercializes cannabinoid-based therapeutics, filed on Tuesday with the SEC to raise up to $50 million in an initial public offering. The Wilshire, United Kingdom-based company, which was founded in 1998 and booked $53 million in sales for the fiscal year ended 9/30/2012, plans to list on the NASDAQ under the symbol GWPH. GW Pharmaceuticals initially filed confidentially on 12/14/2012. Lazard Capital Markets and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.


This article appears in: News Headlines, IPOs

Referenced Stocks:



Latest News Video

Sexual Assault Scandals Rock Military as House Panel Acts
Sexual Assault Scandals Rock Milita...
Shock Over London Killing
Shock Over London Killing           


Sign-in
Existing NASDAQ.com member? Log in here.

By signing into to the site using any of the third-party services above, you agree to NASDAQ.com's Terms of Use.

From Our Trusted News Source





Most Active by Volume:

Company Last Sale Change Net / %
BAC $ 13.31 0.13  0.97%
PFE $ 29.30 0.52  1.81%
GE $ 23.86 0.20  0.85%
F $ 14.97 0.02  0.13%
MSFT $ 34.61 0.24  0.69%
QQQ $ 73.65 0.62  0.83%
MU $ 10.92 0.31  2.76%
INTC $ 24.07 0.08  0.33%